PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC

被引：0
作者：
Vokes, Natalie I. [1 ,2 ]
Le, Xiuning [1 ]
Yap, Timothy A. [1 ,3 ,4 ,5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Therapeut Discovery Div, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Khalifa Inst Personalized Canc Therapy, Houston, TX USA
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 18期
关键词：
CELL LUNG-CANCER; PTEN EXPRESSION; IMPACT;
D O I：
10.1158/1078-0432.CCR-24-1188
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A recent study identified high rates of PI3K-AKT pathway mutations from the FLAURA and AURA3 osimertinib trials and pre-clinically validated that these mutations decreased osimertinib sensitivity in EGFR-mutated non-small cell lung cancer. The AKT inhibitor capivasertib was found to overcome this resistance, providing an important rationale for the development of AKT inhibitors in non-small cell lung cancer.
引用
收藏
页码：3968 / 3970
页数：3
相关论文
共 18 条
  • [1] Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
    Blakely, Collin M.
    Watkins, Thomas B. K.
    Wu, Wei
    Gini, Beatrice
    Chabon, Jacob J.
    McCoach, Caroline E.
    McGranahan, Nicholas
    Wilson, Gareth A.
    Birkbak, Nicolai J.
    Olivas, Victor R.
    Rotow, Julia
    Maynard, Ashley
    Wang, Victoria
    Gubens, Matthew A.
    Banks, Kimberly C.
    Lanman, Richard B.
    Caulin, Aleah F.
    St John, John
    Cordero, Anibal R.
    Giannikopoulos, Petros
    Simmons, Andrew D.
    Mack, Philip C.
    Gandara, David R.
    Husain, Hatim
    Doebele, Robert C.
    Riess, Jonathan W.
    Diehn, Maximilian
    Swanton, Charles
    Bivona, Trever G.
    [J]. NATURE GENETICS, 2017, 49 (12) : 1693 - +
  • [2] Chmielecki J, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-35961-y
  • [3] Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
    Chmielecki, Juliann
    Mok, Tony
    Wu, Yi-Long
    Han, Ji-Youn
    Ahn, Myung-Ju
    Ramalingam, Suresh S.
    John, Thomas
    Okamoto, Isamu
    Yang, James Chih-Hsin
    Shepherd, Frances A.
    Bulusu, Krishna C.
    Laus, Gianluca
    Collins, Barbara
    Barrett, J. Carl
    Hartmaier, Ryan J.
    Papadimitrakopoulou, Vassiliki
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
  • [4] Elamin YY, 2022, J CLIN ONCOL, V40
  • [5] Endoh H, 2006, J THORAC ONCOL, V1, P629
  • [6] PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
    Fang, Wenfeng
    Huang, Yihua
    Gu, Weiguang
    Gan, Jiadi
    Wang, Wenjing
    Zhang, Shiyue
    Wang, Kai
    Zhan, Jianhua
    Yang, Yunpeng
    Huang, Yan
    Zhao, Hongyun
    Zhang, Li
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1258 - +
  • [7] Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations
    Grazini, Ursula
    Markovets, Aleksandra
    Ireland, Lucy
    O'Neill, Daniel
    Phillips, Benjamin
    Xu, Man
    Pfeifer, Matthias
    Vaclova, Tereza
    Martin, Matthew J.
    Bigot, Ludovic
    Friboulet, Luc
    Hartmaier, Ryan
    Cuomo, Maria E.
    Barry, Simon T.
    Smith, Paul D.
    Floc'h, Nicolas
    [J]. CLINICAL CANCER RESEARCH, 2024, 30 (18) : 4143 - 4154
  • [8] Hopcroft L, 2023, NPJ BREAST CANCER, V9, DOI 10.1038/s41523-023-00571-w
  • [9] Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
    Jacobsen, Kirstine
    Bertran-Alamillo, Jordi
    Angel Molina, Miguel
    Teixido, Cristina
    Karachaliou, Niki
    Pedersen, Martin Haar
    Castellvi, Josep
    Garzon, Monica
    Codony-Servat, Carles
    Codony-Servat, Jordi
    Gimenez-Capitan, Ana
    Drozdowskyj, Ana
    Viteri, Santiago
    Larsen, Martin R.
    Lassen, Ulrik
    Felip, Enriqueta
    Bivona, Trever G.
    Ditzel, Henrik J.
    Rosell, Rafael
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [10] Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
    Le, Xiuning
    Puri, Sonam
    Negrao, Marcelo V.
    Nilsson, Monique B.
    Robichaux, Jacqulyne
    Boyle, Theresa
    Hicks, J. Kevin
    Lovinger, Katherine L.
    Roarty, Emily
    Rinsurongkawong, Waree
    Tang, Ming
    Sun, Huiying
    Elamin, Yasir
    Lacerda, Lara C.
    Lewis, Jeff
    Roth, Jack A.
    Swisher, Stephen G.
    Lee, J. Jack
    William, William N., Jr.
    Glisson, Bonnie S.
    Zhang, Jianjun
    Papadimitrakopoulou, Vassiliki A.
    Gray, Jhanelle E.
    Heymach, John V.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6195 - 6203
12